Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 36 clinical trials
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be

  • 0 views
  • 24 Mar, 2022
  • 1 location
Consequences of Mutations in the SPG7 Gene at the Heterozygous State

Paraplegin, encoded by the SPG7 gene, is an ATP-dependent mAAA protease located in the inner mitochondrial membrane. Its function is not fully understood. Mutations in the SPG7 gene are

  • 0 views
  • 07 Jan, 2022
  • 1 location
Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

The purpose of this study is to test the efficacy of an oral, nutrient intervention containing the bioactive components of fish oil to promote healing of chronic venous leg ulcers (CVLUs) by reducing the chronic inflammation at wound sites that prevents healing progression. If this systemic, nutrient intervention is found …

  • 4 views
  • 27 Apr, 2022
  • 1 location
The Late Presenter Treatment Optimisation Study (LAPTOP)

HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in Europe

darunavir
emtricitabine
cobicistat
tenofovir
protease
  • 134 views
  • 16 May, 2022
  • 44 locations
Single-center, Open-label, Single-arm Exploratory Clinical Trial of Anlotinib Monotherapy and Combination Therapy in Relapsed / Refractory MM Previously Treated With Immunomodulator and Protease Inhibitor Regimens

This is a Single-center, Open-label, Single-arm Exploratory Clinical Study to evaluate the safety and efficacy of Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy in relapsed or refractory multiple myeloma patient.

  • 0 views
  • 18 Oct, 2022
  • 1 location
68Ga-FAPI PET/MR for Atherosclerosis

A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade

carotid atherosclerosis
  • 0 views
  • 17 Sep, 2021
  • 1 location
A Phase 2 Double-blind, Randomized Study to Evaluate the Antiviral Activity, Safety, and Efficacy of Orally Administered PBI-0451 Compared With Placebo in Nonhospitalized Symptomatic Adults With COVID-19

This is a phase 2 double-blind, randomized study of PBI-0451 in nonhospitalized symptomatic adults with COVID-19. PBI-0451 is a new chemical entity and inhibitor of the main protease of

  • 0 views
  • 27 Oct, 2022
  • 3 locations
PEskE: A Phase 0/Surgical Window-of-opportunity Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Evolocumab in Patients With Recurrent High-grade Glioma or Glioblastoma

protease inhibitor (PCSK9i) in patients with primary and recurrent World Health Organization (WHO) grade IV malignant glioma. The investigators intend to evaluate whether a clinically licensed PCSK9i

malignant glioma
neutrophil count
renal function
  • 0 views
  • 29 Oct, 2022
  • 1 location
68Ga-FAPI PET/CT in Malignant Tumors

Fibroblast-activation protein (FAP) is a type transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of

primary cancer
pet/ct scan
  • 0 views
  • 12 Sep, 2021
  • 1 location
Inducing Immune Quiescence the Genital Tract With ASA (IIQ-2)

activated T cells, increased levels of systemic T regulatory, increased production of anti-viral anti-protease serpins at the female genital tract and reduced numbers of HIV target cells (mainly CD4+ CCR5

AIDS
Accepts healthy volunteers
protease
HIV Vaccine
  • 0 views
  • 22 Mar, 2022
  • 1 location